GlaxoSmithKline Pakistan reports higher quarterly profit for the quarter ended September 30, 2026

Financial Result

GlaxoSmithKline Pakistan’s quarterly revenue, operating profit, profit after taxation and EPS all increased year on year. No cash dividend was recommended.

Payout

  • No cash dividend

Key Findings

  • Quarterly revenue increased to Rs. 16,594,106 thousand from Rs. 14,188,008 thousand.
  • Quarterly operating profit rose to Rs. 4,160,588 thousand from Rs. 3,248,872 thousand.
  • Quarterly profit after taxation increased to Rs. 2,610,463 thousand from Rs. 2,037,285 thousand; EPS rose to Rs. 8.20 from Rs. 6.40.
  • The board recommended no cash dividend, bonus shares or right shares.

Financial Performance

MetricPreviousQuarter ended September 30, 2025CurrentQuarter ended September 30, 2026Change
Revenue from contracts with customers – netPKR 14.19BPKR 16.59B+17%
Gross profitPKR 5.21BPKR 6.48B+24.4%
Operating profitPKR 3.25BPKR 4.16B+28.1%
Profit after taxationPKR 2.04BPKR 2.61B+28.1%
Earnings per shareRs. 6.40Rs. 8.20+28.1%
Financial (charges) / incomePKR 42.93M-PKR 60.01M-239.8%
Cash and bank balancesPKR 8.59BPKR 8.15B-5.2%
⚡

Highlights summarize the key points from the company's official PSX filing. View the original filing for the complete details before making financial decisions.

More GLAXO announcements

Built for PSX investors

Every filing.Summarised.

Key findings from every PSX announcement, right beside live prices and your portfolio.

Investify company announcements with result figures and filing highlights
Investify announcement summary with key findings from a PSX filing